sinc
pharmaceut
industri
taken
advantag
systemat
advanc
molecular
biologygenet
engin
replac
phenotyp
wholecel
high
throughput
screen
ht
targetbas
screen
assay
targetbas
screen
develop
util
simpl
recombin
protein
enzym
assay
provid
mani
advantag
term
cost
scalabl
reli
assumpt
select
target
fact
best
druggabl
target
given
diseas
howev
last
decad
seen
clear
shift
back
toward
use
phenotyp
screen
initi
start
point
drug
discoveri
especi
neglect
diseas
drug
target
gener
poorli
understood
targetbas
approach
fail
analysi
origin
firstinclass
small
molecul
propos
phenotyp
screen
identifi
novel
inhibitor
approach
year
howev
phenotyp
screen
disadvantag
provid
inform
target
hit
neglect
tropic
diseas
ntd
divers
group
predominantli
communic
diseas
tabl
prevail
tropic
subtrop
condit
affect
countri
billion
peopl
develop
world
cost
global
economi
billion
dollar
everi
year
ntd
disproportion
impact
poorer
region
contribut
substanti
morbid
disabl
poverti
mani
low
middleincom
countri
import
realiz
mani
case
pathogen
eukaryot
parasit
complex
life
cycl
vari
mechan
evad
host
immun
system
addit
parasit
genet
tractabl
laboratori
complic
drug
discoveri
effort
inabl
translat
mani
pathogen
lab
set
one
reason
lack
research
diseas
perhap
critic
absenc
lucr
market
ntd
treatment
diseas
gener
lack
market
incent
spur
product
develop
result
ntd
receiv
rel
littl
research
invest
year
govern
pharmaceut
compani
compar
billion
dollar
invest
diseas
cancer
heart
diseas
blockbust
diseas
although
neglect
diseas
continu
lack
major
econom
incent
due
financi
unattract
affect
popul
tropic
diseas
prioriti
review
voucher
award
compani
success
develop
fdaapprov
treatment
particular
diseas
tabl
ii
overlap
definit
tropic
neglect
diseas
tabl
anticip
assist
compani
focu
develop
treatment
diseas
anoth
way
overcom
challeng
ntd
drug
develop
reposit
repurpos
exist
drug
util
compound
alreadi
approv
fda
compound
known
physicochem
absorpt
distribut
metabol
excret
toxicolog
admet
properti
acceler
develop
process
old
drug
financi
regulatori
hurdl
market
effici
repurpos
approach
especi
critic
ntd
typic
viabl
commerci
product
alreadi
approv
treatment
path
econom
feasibl
addit
potenti
monetari
benefit
develop
reposit
product
shorten
timefram
drug
discoveri
year
year
especi
import
case
spread
diseas
rapid
costli
despit
benefit
drug
repurpos
pharmaceut
compani
seem
make
standard
practic
yet
use
patent
valuabl
synthesi
patent
sinc
repurpos
almost
definit
exclus
limit
use
patent
benefici
pharmaceut
compani
invest
financi
resourc
research
develop
new
compound
potenti
overlook
effect
drug
alreadi
exist
small
drug
compani
biotech
firm
urgent
build
valuabl
ip
order
compet
larger
compani
even
less
like
find
valu
repurpos
drug
due
poor
econom
tradeoff
lot
repurpos
effort
champion
academia
howev
mani
recent
exampl
success
collabor
industri
govern
academia
larg
librari
compound
made
avail
high
throughput
screen
includ
novo
nordisk
novarti
glaxosmith
kline
pfizer
compani
part
consortia
eg
medicin
tb
tb
drug
acceler
nih
ncat
etc
addit
industri
librari
repurpos
studi
benefit
compound
librari
access
includ
ncat
nih
microsourc
lopac
prestwick
broad
calibr
bioactiv
librari
small
molecul
librari
collect
natur
product
other
librari
arguabl
provid
best
benefit
fda
approv
librari
list
seem
updat
sporad
obtain
differ
sourc
studi
refer
librari
fda
approv
drug
describ
librari
rang
compound
johansen
et
al
extend
librari
screen
combin
us
nonu
approv
drug
one
studi
combin
fda
approv
drug
exusapprov
drug
anoth
although
diseas
occur
throughout
globe
impact
type
repurpos
effort
studi
identifi
screen
librari
compil
regulatori
bodi
countri
intent
repurpos
drug
neglect
diseas
knowledg
regulatori
bodi
exist
seem
overlook
research
tri
repurpos
drug
ntd
major
approv
compound
screen
use
us
fda
librari
tremend
progress
made
neglect
diseas
drug
discoveri
last
year
still
mani
gap
address
diseas
variat
associ
terminolog
search
literatur
use
multipl
search
engin
along
highthroughput
screen
identifi
find
paper
screen
perform
success
rare
diseas
often
discuss
alongsid
neglect
diseas
consid
studi
use
medicin
malaria
ventur
mmv
box
extens
hand
studi
present
van
voorhi
et
al
complet
compil
work
also
consider
effort
develop
assay
lead
optim
mechan
action
elucid
smaller
scale
repurpos
studi
neglect
diseas
outsid
scope
investig
due
number
peopl
live
neglect
diseas
urgenc
need
respond
emerg
studi
involv
high
throughput
screen
dengu
zika
ebola
virus
includ
recent
exampl
addit
present
work
done
ntd
repurpos
field
compil
databas
compound
suggest
repurpos
author
develop
across
mani
studi
summar
herein
chaga
diseas
ntd
known
caus
kinetoplastid
parasit
trypanosoma
cruzi
diseas
problem
latin
america
endem
also
increasingli
found
north
america
europ
reach
immigr
clinic
sign
chaga
diseas
manifest
differ
phase
case
diseas
ultim
lead
death
avail
conting
plan
reli
organ
transplant
spread
chaga
diseas
north
america
beyond
highlight
need
novel
safe
effect
therapeut
treat
cruzi
infect
targetbas
phenotypicbas
studi
perform
recent
year
address
de
rycker
et
al
employ
novel
screen
cascad
screen
two
librari
selleckchem
compris
fdaapprov
drug
nih
clinic
collect
consist
compound
test
clinic
trial
drug
concentr
cascad
made
initi
singlepoint
primari
screen
follow
high
content
screen
assay
determin
potenc
staticcid
rateofkil
assess
well
vitro
activ
determin
measur
inhibit
agonistinduc
calcium
flux
inhibitor
found
interfer
calcium
homeostasi
shown
moder
slow
kill
profil
despit
high
potenc
remain
hit
classifi
central
nervou
system
cn
target
lipophil
amin
base
potenc
select
cidal
profil
interest
drug
determin
ifenprodil
ziprasidon
clemastin
clofibr
azelastin
compound
reason
bioavail
current
limit
toxic
futur
work
would
perform
elimin
cn
penetr
antagon
make
compound
suitabl
treatment
cruzi
human
target
develop
mention
assay
riley
et
al
identifi
sever
hit
mention
briefli
separ
paper
use
enzym
chaga
parasit
express
e
coli
way
distinguish
compound
similar
mechan
action
use
current
drug
resist
grow
problem
compound
initi
screen
activ
result
hit
compound
repres
compound
class
compound
depriorit
base
chemic
similar
known
treatment
remain
hit
repres
singleton
suggest
repurpos
keenan
et
al
util
luminesc
cellbas
ht
order
identifi
inhibitor
cruzi
replic
select
compound
screen
base
abil
inhibit
intracellular
trypanosom
replic
insid
host
cell
surviv
parasit
assess
via
detect
luminesc
report
cell
lyse
group
screen
compound
identifi
hit
rate
compound
list
priorit
base
follow
characterist
homolog
known
antifung
pharmacophor
antitrypanosom
activ
compound
contain
basic
heterocycl
two
addit
lipophil
aromat
moieti
trigon
tetrahedr
arrang
around
central
atom
synthet
tractabl
novel
structur
field
extent
structur
domain
influenc
activ
fifteen
lead
hit
structur
initi
identifi
base
mention
criteria
seven
identifi
vitro
activ
studi
trypanosoma
cruzi
vivo
studi
toxic
filter
candid
um
promis
therapeut
chaga
diseas
planer
et
al
suggest
two
combin
therapi
treatment
chaga
diseas
amlodipin
clemastin
combin
posaconazol
drug
screen
dramat
effect
alon
except
benznidazol
posaconazol
howev
note
mani
compound
ineffect
vitro
investig
intent
use
low
dosag
order
observ
effect
bloodstream
parasitemia
genom
cruzi
sever
enzymat
pathway
identifi
potenti
target
compound
associ
pathway
investig
bayesian
model
consid
small
molecul
previou
studi
silico
screen
compound
screen
vitro
found
activ
sever
found
quit
effect
vivo
mice
one
compound
pyronaridin
efficaci
select
investig
find
new
inhibitor
cruzain
enzym
present
trypanosoma
cruzi
wigger
et
al
screen
zinc
databas
compound
leadlik
properti
perform
consensu
score
use
targetbas
molecular
dock
ligand
base
similar
search
narrow
million
compound
compound
screen
glide
xp
hqsar
top
compound
pass
screen
visual
inspect
compound
select
vitro
test
top
two
compound
screen
structur
character
xray
crystallographi
understand
bind
mode
cruzain
gunatillek
et
al
screen
compound
multipl
librari
observ
sever
compound
contain
similar
structur
featur
effect
chaga
diseas
use
permiss
target
small
molecul
assay
top
hit
nitrogencontain
aromat
heterocycl
pharmacophor
compound
r
group
para
posit
nitrogen
meta
posit
within
ring
compound
ad
zinc
databas
futur
use
vitro
verif
perform
yet
unfortun
due
complex
diseas
variou
stage
parasit
lifecycl
inher
differ
human
patient
vivo
vitro
silico
studi
compound
show
great
promis
preclin
studi
necessarili
translat
effect
clinic
approach
chaga
diseas
evid
case
posaconazol
fail
maintain
sustain
efficaci
cours
day
clinic
trial
contrast
benznidazol
current
util
treatment
shown
separ
studi
sustain
respons
year
unfortun
benznidazol
known
side
effect
limit
broad
use
major
project
dndi
find
superior
treatment
option
updat
filter
compound
inhibitor
like
posaconazol
better
understand
rate
kill
predict
slow
act
versu
fast
act
compound
human
african
trypanosomiasi
hat
anoth
kinetoplastid
diseas
found
subsaharan
africa
million
peopl
risk
diseas
estim
current
infect
hat
known
caus
two
differ
subspeci
protozoan
parasit
trypanosoma
brucei
treatment
diseas
hat
drug
histor
limit
relat
administr
toxic
cost
rel
altern
drug
valid
drug
target
drive
research
identifi
parasitespecif
antitrypanosom
lead
compound
henc
effort
develop
fluorometr
viabil
assay
ht
success
exampl
partnership
industri
academia
compound
provid
glaxosmithklin
screen
diaz
et
al
growth
inhibit
trypanosoma
brucei
compound
show
activ
sleep
sick
parasit
also
present
sign
toxic
human
cell
analysi
perform
distinguish
cell
death
vs
cell
growth
inhibit
compound
caus
parasit
death
group
cluster
base
structur
similar
blaazer
et
al
investig
librari
compound
fragment
effici
cover
chemic
space
defin
complex
number
ring
begin
compound
screen
compound
vitro
phosphodiesteras
pde
present
brucei
ortholog
human
fragment
display
activ
assay
fragment
show
select
author
focus
fragment
structur
similar
known
drug
scaffold
associ
analog
phenotyp
assay
parasit
caus
sleep
sick
chaga
leishmaniasi
malaria
well
human
cell
select
consider
piclamilast
identifi
bland
et
al
phosphodiesteras
pde
inhibitor
potenti
use
hat
approach
involv
interest
method
aim
repurpos
knowledg
phosphodiesteras
inhibitor
humanfocus
medicin
chemistri
leverag
understand
treatment
hat
parasit
identifi
piclamilast
known
pde
inhibitor
human
relev
start
place
optim
follow
comparison
piclamilast
dock
human
parasit
bind
pocket
well
sar
studi
analog
parasit
transmit
sandfli
caus
differ
clinic
manifest
depend
infect
speci
host
immun
system
diseas
endem
countri
year
million
peopl
infect
approxim
million
risk
least
four
treatment
option
current
avail
includ
antimoni
amphotericin
b
miltefosin
paromomycin
none
adapt
field
main
drawback
treatment
toxic
long
treatment
cours
need
hospit
high
cost
resist
promis
candid
discoveri
develop
pipelin
reli
combin
therapi
highthroughput
highcont
imagebas
cellbas
assay
use
human
macrophag
cell
line
infect
intracellular
leishmania
sp
also
develop
nuh
et
al
develop
experiment
valid
novel
axen
leishmania
vitro
assay
specif
use
identifi
cytocid
compound
less
falseposit
assay
use
novel
assay
screen
compound
primari
screen
found
activ
hit
inact
compound
hit
compar
result
intracellular
assay
shown
activ
hit
hit
inact
intracellularli
may
suggest
target
essenti
intracellularli
result
demonstr
new
assay
could
robustli
predict
intracellular
amastigot
leishmania
stage
current
gold
standard
vitro
drug
screen
de
rycker
descript
assay
optim
leishmania
also
result
hit
compound
two
parallel
studi
author
perform
amastigot
axen
assay
readili
adapt
high
throughput
differenti
compound
kill
parasit
vs
slow
growth
author
screen
almost
compound
show
activ
toward
amastigot
fail
perform
extent
physiolog
relev
intramacrophag
assay
author
develop
hit
select
leishmania
compar
human
lung
cell
exhibit
doserespons
relationship
intracellular
leishmania
sanderson
et
al
use
vitro
vivo
methodolog
found
sever
kinas
inhibitor
well
compound
sorafenib
sunitinib
lapatinib
amphotericin
miltefosin
use
cancer
therapi
also
effect
leishmania
sever
studi
consid
multipl
kinetoplastid
extens
work
perform
pena
et
al
order
identifi
potenti
new
drug
wholecel
phenotyp
assay
leishmania
donovani
trypanosoma
cruzi
trypanosoma
brucei
use
screen
glaxosmithklin
ht
divers
set
million
compound
three
screen
use
orthogon
assay
conduct
ensur
compound
genuin
activ
identifi
enabl
compound
interf
assay
rule
select
candid
start
first
potent
specif
noncytotox
compound
doserespons
output
screen
also
filter
leadlik
compound
final
box
contain
compound
compound
activ
leishmania
donovani
activ
trypanosoma
cruzi
activ
trypanosoma
brucei
kinas
frequent
target
class
select
inhibitor
compound
box
mostli
compris
heterocycl
moieti
bind
cytochrom
metal
group
nitrosubstitut
aryl
group
includ
nitropyrazol
nitrotriazol
nitrofuran
nitrothiophen
nitrobenzen
khare
et
al
screen
million
compound
three
kinetoplastid
identifi
number
compound
activ
select
index
greater
also
synthes
compound
optim
produc
azabenzoxazol
compound
activ
three
speci
work
also
perform
multipl
kinetoplastid
use
mmv
malaria
box
van
voorhi
et
al
review
screen
perform
mani
differ
group
use
malaria
box
varieti
repurpos
effort
kaiser
et
al
perform
hand
studi
screen
compound
malaria
box
bloodstream
b
rhodesiens
brucei
intracellular
amastigot
cruzi
l
infantum
compound
pass
initi
vitro
screen
fail
vivo
test
year
kaiser
et
al
took
drug
high
likelihood
repurpos
test
sever
neglect
tropic
diseas
parasit
test
potent
compound
mous
model
variou
diseas
mix
result
activ
b
rhodesiens
show
antidepress
sertralin
paroxetin
good
repurpos
candid
sever
report
first
time
moder
antichaga
efficaci
tadalafil
erectil
dysfunct
drug
mebeverin
antispasmod
promazin
nortriptylin
also
identifi
studi
antimalari
compound
alongsid
sever
tricycl
antidepress
schistosomiasi
caus
blood
fluke
flatworm
infect
approxim
million
peopl
worldwid
parasit
found
freshwat
harbor
appropri
vector
snail
activ
invad
skin
children
play
water
particularli
risk
matur
male
femal
fluke
mate
lay
egg
elicit
varieti
immunoinflammatori
respons
lead
lifetim
pain
malais
interfer
school
attend
abil
work
consequ
neg
impact
person
wellb
commun
develop
schistosomiasi
also
increas
risk
acquir
hiv
infect
treatment
control
schistosomiasi
reli
mass
drug
administr
mda
one
drug
praziquantel
develop
year
ago
apart
obviou
worri
drug
resist
pzq
fail
particularli
use
dramat
expand
next
decad
drug
number
pharmaceut
pharmacolog
weak
encourag
search
better
chemotherapi
howev
unlik
situat
malaria
protozo
diseas
even
soiltransmit
helminth
sth
discuss
transnat
organ
discoveri
develop
program
find
better
drug
littl
evid
situat
chang
anytim
soon
therefor
much
effort
identifi
new
antischistosom
drug
occur
academ
set
search
new
chemic
matter
last
decad
wit
number
advanc
wholeorgan
phenotyp
screen
paradigm
includ
use
viabil
vitalitybas
singemetr
assay
review
partial
fullyquantit
imag
analysi
approach
regardless
format
assay
focus
postinfect
larva
schistosomula
rel
abund
stage
parasit
schistosoma
mansoni
model
schistosom
allow
reason
screen
throughput
use
larval
parasit
ration
basi
target
product
profil
tpp
new
antischistosom
drug
encompass
activ
immatur
schistosom
matur
parasit
case
pzq
hit
identifi
schistosomula
screen
vitro
activ
limit
adult
parasit
must
harvest
small
anim
mice
hamster
consid
vivo
efficaci
studi
stage
tier
approach
involv
screen
chemic
divers
focus
chemic
collect
identifi
varieti
antischistosom
chemistri
includ
antibiot
eg
doramectin
clofazimin
neuroact
anticanc
agent
eg
trametinib
vandetanib
proteas
inhibitor
thiosemicarbazon
statin
drug
use
hypercholesterolemia
studi
may
highlight
mansour
et
al
obtain
compound
multipl
librari
ie
pfizer
gsk
perform
highthroughput
screen
compound
schistosomula
follow
hitscreen
juvenil
matur
parasit
eventu
priorit
seven
compound
futur
studi
none
alreadi
approv
drug
ingramsieb
et
al
studi
antischistosom
properti
mmv
malaria
box
compris
divers
druglik
probelik
compound
confirm
vitro
activ
plasmodium
falciparum
malaria
five
compound
identifi
lead
compound
compound
n
compound
promis
compound
focu
futur
antischistosom
studi
vivo
studi
mice
infect
schistosoma
mansoni
show
singl
oral
dose
mgkg
two
drug
reduc
worm
burden
n
two
drug
repres
use
scaffold
prepar
futur
small
molecul
inhibitor
mansoni
apart
wholeorgan
screen
approach
defin
novel
antischistosom
employ
liu
et
al
identifi
multipl
compound
repurpos
schistosomiasi
perform
high
throughput
dock
screen
molecul
enzym
reductas
involv
fatti
acid
synthesi
compound
test
directli
inhibit
worm
studi
cell
toxic
result
final
compound
impact
mortal
rate
exhibit
low
cytotox
human
cell
enzym
involv
epigenet
function
schistosoma
mansoni
select
target
high
throughput
screen
anoth
studi
homolog
model
kannan
et
al
abl
perform
dock
compound
class
known
zinc
bind
capabl
screen
compound
select
vitro
test
compound
show
good
toxic
parasit
enzym
consid
lead
compound
li
et
al
implement
high
throughput
screen
synthet
compound
target
schistosoma
mansoni
thioredoxin
glutathion
reductas
smtgr
wellcharacter
drug
target
schistosoma
mansoni
compound
show
concentrationdepend
inhibitori
trend
thioredoxin
glutathion
reductas
test
cultur
larva
show
compound
cidal
activ
within
hour
three
compound
kill
adult
worm
ex
vivo
concentr
target
enzym
use
integr
approach
neve
et
al
develop
qsar
model
smtgr
appli
virtual
screen
commerci
databas
compound
comput
approach
allow
select
virtual
hit
test
use
high
content
screen
assay
schistosomula
adult
worm
six
compound
activ
schistosomula
three
activ
adult
worm
hit
rate
among
vinyl
pyridin
benzylsulfonyl
two
compound
repres
new
chemic
scaffold
show
inhibitori
effect
equival
pzq
valu
around
schistosomula
adult
worm
repres
promis
new
antischistosom
hit
hittolead
optim
composit
approach
involv
wholeorgan
targetbas
strategi
recent
employ
discov
valid
phosphodiesteras
schistosom
drug
target
use
benzoxaborol
inhibitor
human
notabl
studi
employ
transgen
line
c
elegan
express
schistosom
order
function
character
valid
target
final
chemogenom
cheminformat
strategi
employ
identifi
possibl
novel
target
antischistosom
drug
discoveri
neve
et
al
consid
protein
concept
similar
target
similar
drug
use
protein
search
drug
databas
find
drug
activ
schistosoma
flatworm
addit
find
sever
compound
confirm
posit
activ
suggest
untest
compound
potenti
repurpos
follow
studi
author
test
suggest
drug
previou
studi
schistosomula
adult
mansoni
worm
use
spectrophotometr
assay
autom
imagebas
assay
accur
measur
parasit
viabil
motil
respect
found
paroxetin
antidepress
drug
show
pronounc
effect
schistosomula
viabil
h
incub
valu
motil
reduct
male
femal
worm
h
exposur
respect
burn
et
al
use
c
elegan
model
system
parasit
nematod
otherwis
difficult
screen
identifi
compound
lethal
rescreen
hit
two
parasit
nematod
infect
livestock
two
vertebr
model
way
determin
degre
select
interestingli
note
nematicid
compound
higher
logp
octanolwat
partit
coeffici
rest
compound
screen
mathew
et
al
took
similar
approach
screen
compound
multipl
librari
initi
identifi
compound
activ
c
elegan
focus
compound
impact
growth
fecund
group
compound
accord
tanimoto
similar
identifi
compound
fell
cluster
previous
describ
burn
studi
compound
structur
featur
belong
previous
suggest
nematocid
compar
activ
compound
repres
nematod
mammalian
yeast
cell
structureact
relationship
sar
compar
genom
sequenc
consid
gain
understand
potenti
risk
resist
develop
describ
drug
discoveri
process
inher
difficult
find
compound
effect
present
varieti
mechan
action
import
combat
resist
turn
requir
larg
librari
screen
crowther
et
al
also
recogn
need
larg
screen
parasit
nematod
like
brugia
malayi
caus
agent
lymphat
filariasi
lymphat
filariasi
river
blind
two
relat
diseas
togeth
affect
million
peopl
associ
debilit
symptom
neglect
diseas
stand
benefit
broadspectrum
nematocid
screen
describ
andor
target
specif
screen
unfortun
screen
almost
compound
c
elegan
contain
workflow
identifi
compound
effect
brugia
malayi
particularli
low
concentr
result
discuss
druggabl
protein
target
paradox
discuss
need
qualiti
protein
target
worth
expenditur
high
throughput
screen
difficulti
determin
protein
promis
resourc
spent
reason
group
prefer
use
smaller
enrich
librari
compound
bilsland
et
al
develop
assay
express
gene
target
protein
worm
human
counterpart
brugia
malayi
parasit
yeast
abl
screen
compound
malaria
box
found
sever
select
compound
test
vitro
sever
compound
kill
adult
parasit
other
impact
growth
motil
signific
manner
import
sinc
major
symptom
diseas
associ
parasit
adult
form
lack
drug
function
stage
initi
screen
improv
likelihood
compound
abl
taken
live
organ
consid
multipl
filariid
nematod
bulman
et
al
screen
fdaapprov
librari
adult
worm
brugia
spp
microfilaria
onchocerca
onchengi
thirdstag
larva
onchocerca
volvulu
microfilaria
onchocerca
ochengi
loa
loa
drug
candid
first
select
use
wormin
assay
adult
femal
brugia
measur
adult
worm
motil
respons
drug
compound
inhibit
motil
screen
volvulu
molt
larva
ochengi
adult
worm
mtt
assay
motil
assay
bulman
et
al
found
auranofin
gold
contain
compound
first
develop
treat
rheumatoid
arthriti
effect
kill
adult
brugia
ochengi
worm
inhibit
larval
volvulu
molt
thirdstag
larva
fourthstag
larva
auranofin
next
test
vivo
gerbil
infect
b
pahangi
measur
burden
brugia
adult
worm
treatment
day
mgkg
gold
plasma
level
also
measur
gerbil
assess
circul
time
drug
base
previou
studi
bulman
et
al
hypothes
mechan
auranofin
inhibit
might
due
auranofin
target
thioredoxin
reductas
thioredoxin
glutathion
reductas
tgr
stadelmann
et
al
evalu
vitro
efficaci
mmv
malaria
box
treatment
echinococcu
multiloculari
parasit
worm
caus
alveolar
echinococcosi
deadli
helminth
infect
author
first
util
pgi
assay
measur
level
enzym
phosphoglucos
isomeras
pgi
releas
damag
narrow
malaria
box
compound
demonstr
physic
damag
metacestod
prolif
form
echinococcu
multiloculari
howev
seven
twentyfour
compound
activ
doserespons
assay
demonstr
two
seven
compound
valu
activ
drug
pgi
screen
also
assess
vitro
toxic
human
foreskin
fibroblast
hff
reuber
rat
hepatoma
rh
cell
cell
seed
plate
compound
ad
hour
five
day
viabil
cell
assess
cascad
vitro
screen
describ
led
identif
compound
potenti
treatment
echinococcu
multiloculari
infect
howev
result
could
reproduc
vivo
test
mous
model
johnston
et
al
screen
approxim
drug
approv
use
human
assay
wolbachia
endosymbiot
bacteria
filari
nematod
drug
screen
hit
oral
avail
fifteen
select
screen
minocyclin
methacyclin
sparfloxacin
antibiot
rifapentin
antitb
activ
mous
model
love
et
al
use
wholecel
phenotyp
screen
platform
test
librari
small
molecul
cryptosporidium
parvum
caus
diarrhea
associ
signific
mortal
develop
countri
two
librari
compound
use
studi
name
bioactiv
compound
set
assembl
california
institut
biomed
research
calibr
global
health
chemic
divers
librari
ghcdl
obtain
univers
dunde
drug
discoveri
unit
vitro
cultiv
cryptosporidium
yet
establish
vivo
oocyst
propag
c
parvum
calv
use
studi
five
potent
compound
c
parvum
found
go
nm
monensin
nm
clofazimin
nm
cyclosporin
nm
nm
go
known
potent
inhibitor
protein
kinas
c
tyrosin
kinas
jak
also
known
telomeras
inhibitor
ix
potent
revers
inhibitor
telomeras
activ
arrest
cell
phase
cell
cycl
cyclosporin
rel
old
drug
inhibitor
phosphatas
activ
calcineurin
well
known
potent
immunosuppress
properti
monensin
inonophor
antibiot
ad
cattl
feed
final
clofazimin
fdaapprov
drug
use
treatment
leprosi
recent
also
evalu
tuberculosi
howev
clofazimin
show
promis
safeti
profil
futur
work
still
need
establish
whether
clofazimin
target
parasit
pathway
modul
hostmedi
pathway
essenti
parasit
prolifer
sever
librari
previous
fdaapprov
medic
assess
abil
inhibit
growth
bacteria
borrelia
burgdoferi
caus
agent
lyme
diseas
north
america
studi
compound
identifi
top
character
activ
standard
phenotyp
screen
perform
use
malaria
box
two
differ
protist
toxoplasmosi
wide
spread
diseas
fatal
develop
fetus
individu
weaken
immun
system
entamoeba
histolytica
diseas
especi
pronounc
subsaharan
africa
mortal
rate
near
malaria
toxoplasmosi
seven
compound
identifi
exhibit
select
index
greater
compound
compar
current
use
antitoxoplasmosi
drug
determin
overlap
scaffold
type
indic
structur
novelti
compound
particular
repurpos
effort
benefici
case
drugresist
emerg
two
compound
similarli
identifi
repurpos
entamoeba
histolytica
dengu
vectorborn
diseas
caus
death
year
place
nearli
half
world
popul
risk
presenc
multipl
serotyp
challeng
success
antivir
strategi
place
immun
strategi
disadvantag
diseas
progress
dengu
hemorrhag
fever
also
call
sever
dengu
like
occur
secondari
infect
potenti
fatal
review
lim
et
al
summar
import
work
concern
repurpos
dengu
discuss
two
strategi
use
dengu
drug
therapi
name
inhibit
viral
target
inhibit
host
target
recent
work
cruz
et
al
cellbas
screen
small
molecul
perform
differ
serotyp
dengu
viru
host
cell
result
activ
compound
gener
structur
scaffold
compound
toxic
host
cell
viru
would
die
test
would
distinguish
two
effect
sever
scaffold
compound
identifi
toxic
multipl
sourc
dengu
viru
use
confoc
microscopi
timeofaddit
assay
insight
gain
potenti
mechan
action
broadspectrum
hit
determin
interf
viral
entri
like
block
viru
assembl
hypothes
base
structur
similar
morewel
studi
dasatinib
high
throughput
screen
yang
et
al
screen
compound
singl
concentr
identifi
potenti
smallmolecul
inhibitor
dengu
viru
quaternari
ammonium
salt
inhibit
replic
viral
rna
synthesi
four
serotyp
japanes
enceph
viru
jev
without
appar
cytotox
stabl
reporterdenv
replicon
cell
line
use
screen
potenc
inhibitor
also
demonstr
substitut
region
caus
resist
viru
suggest
inhibitor
target
proteas
inhibit
viral
replic
rna
synthesi
futur
work
need
understand
mechan
interact
protein
inhibit
denv
replic
cheung
et
al
conduct
screen
us
drug
librari
collect
microsourc
discoveri
system
inc
gaylordsvil
ct
usa
use
immunofluoresc
base
phenotyp
screen
assay
lanatosid
c
cardiac
glycosid
inhibit
low
cytotox
author
suggest
compound
inhibit
earli
process
denv
replic
cycl
furthermor
test
lanatosid
c
differ
denv
serotyp
positivestrand
rna
virus
found
effect
inhibit
serotyp
denv
flaviviru
kunjin
alphaviru
chikungunya
sindbi
viru
well
human
enteroviru
fluorescencebas
high
throughput
assay
test
denv
helicas
activ
use
screen
librari
compound
obtain
experiment
therapeut
centr
singapor
among
compound
suramin
sleep
sick
drug
shown
inhibit
denv
helicas
compound
present
noncompetit
mode
inhibit
ki
indic
abl
bind
apo
form
enzym
immunofluoresc
imagebas
assay
identifi
csrc
protein
kinas
inhibitor
dasatinib
saracatinib
potent
blocker
denv
serotyp
murin
flaviviru
modoc
srcfamili
kinas
hypothes
import
role
regul
denv
replic
base
select
profil
compound
exhibit
antidenv
activ
primari
secondari
screen
studi
also
screen
collect
known
inhibitor
mammalian
serthr
tyr
kinas
zika
viru
zikv
well
known
arthropodborn
flaviviru
famili
flavivirida
phylogenet
close
dengu
viru
yellow
fever
transmit
aed
mosquito
usual
caus
mild
denguelik
ill
possibl
fever
joint
pain
rash
andor
swollen
lymph
node
viru
associ
sever
studi
rare
syndrom
sever
neurolog
disord
zikv
emerg
due
outbreak
major
public
health
threat
america
world
health
organ
deem
cluster
microcephali
case
identifi
well
incid
neurolog
disord
associ
zikv
latin
america
caribbean
classifi
zika
constitut
public
health
emerg
intern
concern
pheic
other
describ
step
could
taken
initi
drug
discoveri
program
zikv
includ
comput
repurpos
also
describ
use
world
commun
grid
project
call
openzika
assist
antivir
drug
discoveri
sever
approach
repurpos
drug
zika
viru
attempt
recent
year
respond
recent
outbreak
barrow
et
al
screen
fda
approv
drug
antizika
activ
sever
select
extend
screen
multipl
type
human
tissu
relev
zika
surviv
transmiss
importantli
author
also
consid
rel
risk
identifi
compound
use
pregnanc
candid
drug
three
fell
pregnanc
categori
b
describ
anim
reproduct
studi
fail
demonstr
risk
fetu
adequ
wellcontrol
studi
pregnant
women
three
compound
categori
daptomycin
mefloquin
hcl
palonosetron
hcl
daptomycin
antimicrobi
mefloquin
hcl
antiparasit
disrupt
autophagi
palonosetron
hcl
receptor
antagonist
drug
interact
ssri
compound
identifi
antizika
activ
c
pregnanc
categori
advers
effect
observ
either
human
anim
pascoalino
et
al
develop
valid
util
assay
zika
viru
screen
nih
clinic
collect
found
structur
divers
select
antizika
compound
compound
lovastatin
hypolipidem
agent
anticanc
agent
broad
spectrum
antimetabolit
palomosetron
antagonist
kitasamycin
macrolid
broad
spectrum
antibiot
xu
et
al
observ
increas
activ
zika
infect
cell
use
inform
develop
assay
screen
multipl
librari
combin
compound
initi
compound
identifi
hit
emricasan
niclosamid
show
signific
activ
without
cytotox
studi
combin
addit
behavior
observ
retallack
et
al
perform
highthroughput
screen
fdaapprov
drug
emphasi
drug
known
safe
pregnanc
screen
perform
monitor
inhibit
virusdepend
cell
death
vero
cell
author
show
antibiot
azithromycin
reduc
viral
prolifer
glial
cell
low
toxic
outbreak
spread
ebola
viru
ebov
west
africa
highlight
clear
need
new
antivir
drug
similar
emerg
virus
research
group
previous
undertaken
high
throughput
screen
identifi
sever
alreadi
approv
drug
demonstr
vitro
growth
inhibitori
activ
ebov
studi
kouznetsova
et
al
use
assay
identifi
compound
block
ebola
vlp
viruslik
particl
entri
host
cell
fdaapprov
drug
screen
compound
identifi
potent
group
microtubul
inhibitor
group
identifi
hit
larger
librari
compound
author
went
propos
screen
ncat
librari
use
assay
develop
previous
johansen
et
al
screen
food
drug
administr
fda
approv
drug
molecular
probe
engin
strain
identifi
sever
compound
activ
ebola
zair
viru
clomiphen
toremifen
tamoxifen
raloxifen
particularli
effect
estrogen
receptor
antagonist
along
diethylstilbestrol
lesser
extent
quinestrol
equilin
hydroxyprogesteron
caproat
er
agonist
also
provid
antivir
activ
extens
work
perform
multipl
cell
line
investig
select
two
year
later
group
screen
librari
us
nonu
approv
drug
vitro
high
throughput
screen
ebola
eighti
compound
consid
initi
hit
select
screen
eventu
top
compound
confirm
mous
efficaci
studi
edward
et
al
optim
ebola
minigenom
assay
test
librari
compound
transfect
cell
move
test
compound
biosafeti
level
condit
infecti
viru
mycophenol
acid
gedunin
show
quit
promis
result
significantli
reduc
viru
replic
low
cytotox
exhaust
studi
perform
anantpadma
et
al
small
molecul
screen
high
concentr
ebola
marburg
viru
like
particl
transduc
hela
cell
sever
step
screen
reduc
final
hit
compound
activ
virus
cheng
et
al
transfect
human
kidney
cell
plasmid
multipl
viru
type
includ
marburg
ebov
hiv
creat
pseudovirion
high
throughput
assay
investig
prestwick
chemic
librari
discov
compound
effect
marburg
ebov
strike
number
hit
gpcr
gprotein
coupl
receptor
antagonist
provid
addit
insight
potenti
mechan
action
specif
time
addit
studi
indic
inhibitor
block
viral
entri
initi
attach
cell
fusion
either
direct
antagon
indirectli
via
gpcr
initi
cell
signal
combin
compound
identifi
studi
divers
structur
target
histamin
receptor
serotonin
receptor
muscarin
acetylcholin
receptor
adrenerg
receptor
found
block
viral
entri
clozapin
trimipramin
maleat
salt
fell
list
categori
compound
list
target
benztropin
display
broad
spectrum
antifiloviru
activ
multipl
isol
ebov
marv
wang
et
al
perform
screen
fdaapprov
drug
use
ebov
zair
strain
ebola
viru
gphiv
core
pseudoviru
contain
firefli
luciferas
report
gene
order
identifi
new
target
treatment
ebola
compound
compound
greater
inhibit
pebov
compound
compound
less
inhibit
vesicular
stomat
viru
pvsv
identifi
select
primari
hit
valid
primari
hit
cytotox
compound
assess
parallel
without
pseudoviru
necessari
rule
compound
inhibit
fluc
express
hiv
replic
two
compound
identifi
hit
includ
teicoplanin
glycopeptid
antibiot
use
treatment
gramposit
bacteri
infect
toremiphen
teicoplanin
select
character
demonstr
complet
inhibit
ebov
without
appar
cytotox
make
ideal
candid
treatment
ebola
bayesian
machin
learn
model
develop
use
data
set
previou
drug
screen
ebola
viru
data
use
gener
bayesian
model
use
score
microsourc
spectrum
librari
predict
compound
would
display
antiebola
activ
quinacrin
pyronaridin
tiloron
identifi
activ
success
confirm
vitro
good
potenc
recent
tiloron
shown
efficaci
mous
model
ebola
infect
mirza
et
al
consid
two
target
protein
ebovz
viru
virtual
screen
compound
filter
compound
much
larger
compil
librari
includ
phytochem
compound
natur
product
protein
crystal
structur
avail
energi
minim
use
charmm
protein
strain
ebola
without
resolv
crystal
structur
homolog
model
energi
minim
dock
hit
consid
base
predict
admet
properti
select
studi
author
perform
retrospect
analysi
known
vitro
knowledg
literatur
aggreg
predict
account
would
like
fals
posit
vitro
assay
date
vitro
valid
zhao
et
al
use
homolog
model
enzym
critic
ebolahuman
interact
use
molecular
dynam
find
conform
found
screen
fda
approv
drug
nucleotidenucleosid
drug
investig
dock
pose
multipl
dock
program
compar
compound
final
select
potenti
activ
test
vitro
vivo
ebola
chopra
et
al
conduct
high
throughput
screen
compound
known
side
effect
includ
fda
approv
drug
almost
protein
structur
interpret
result
drugprotein
interact
led
compound
previous
establish
activ
ebola
previou
vitro
work
novel
suggest
provid
cando
approach
suggest
experiment
follow
although
perform
madrid
et
al
screen
fdaapprov
drug
multipl
dosag
multipl
biolog
threat
agent
includ
ebola
marburg
viru
lassa
viru
bacillu
anthraci
francisella
tularensi
coxiella
burnetii
caus
agent
anthrax
tularemia
q
fever
respect
initi
inhibit
compar
posit
control
bafilomycin
virus
ciproflaxin
bacteria
compound
perform
compar
within
two
standard
deviat
select
intracellular
screen
hit
narrow
select
compound
broad
activ
one
bacteria
viru
ebola
dataset
studi
subsequ
use
machin
learn
model
describ
earlier
mudhasani
et
al
investig
librari
proteas
inhibitor
rift
valley
fever
viru
rvfv
compound
chemdiv
librari
screen
compound
result
inhibit
four
distinct
structur
type
time
addit
studi
also
perform
gain
insight
mechan
action
ie
compound
involv
viru
entri
viral
rna
transcript
inhibit
protein
synthesi
disrupt
cruz
et
al
perform
similar
work
screen
librari
kinas
inhibitor
chikungunya
viru
identifi
compound
provid
greater
inhibit
dose
depend
character
imagebas
screen
karla
et
al
util
host
genomewid
lossoffunct
screen
valid
provir
antivir
host
factor
sixteen
factor
relev
multipl
virus
repres
central
biolog
node
antivir
therapeut
intervent
valid
sixteen
factor
technolog
use
gener
cell
defici
gene
function
respons
observ
gene
enrich
analysi
use
analyz
biolog
process
molecular
function
requir
viral
infect
karla
et
al
next
assess
antivir
activ
chemic
compound
target
identifi
provir
factor
involv
chikungunya
replic
util
special
drug
databas
identifi
compound
interact
gene
product
distinct
chikungunya
provir
gene
compound
shown
interact
six
distinct
provir
factor
pathway
rnai
rna
interfer
screen
show
five
six
provir
factor
druggabl
special
knockout
mice
gener
studi
result
vivo
demonstr
tivozanib
significantli
reduc
chikungunya
viral
load
vital
organ
pimozid
calmodulin
inhibitor
tofa
fatti
acid
synthesi
inhibitor
also
show
promis
result
vivo
dyall
cowork
suggest
use
emetin
dihydrochlorid
hydrat
antibacteri
agent
sever
compound
combat
merscov
sarscov
author
began
exclus
librari
approv
drug
shown
vitro
activ
test
relev
cell
line
viru
strain
consist
compound
found
efficaci
one
virus
test
awar
other
perform
analysi
across
compound
identifi
repurpos
screen
therefor
curat
molecul
deriv
variou
drug
repurpos
effort
calcul
molecular
properti
compound
sever
molecular
descriptor
gener
compound
use
discoveri
studio
version
biovia
san
diego
ca
summari
statist
perform
use
jmp
cari
nc
tabl
iii
figur
show
compound
mean
properti
similar
druglik
properti
summar
previous
particular
find
averag
mw
gmol
less
number
hbond
donor
less
hbond
acceptor
less
averag
octanolwat
partit
coeffici
less
sinc
major
compound
identifi
screen
larg
librari
bioactiv
fda
approv
drug
etc
result
entir
surpris
sever
ntd
dataset
develop
bayesian
model
use
assay
central
dataset
publish
other
exampl
chaga
diseas
ebola
zika
etc
figur
sever
recent
public
describ
assay
central
detail
well
made
comparison
algorithm
ntd
model
therefor
use
score
input
molecul
priorit
test
ongo
lab
collabor
work
expand
upon
previou
effort
chaga
ebola
diseas
tuberculosi
believ
consider
opportun
drug
discoveri
could
achiev
mine
grow
public
dataset
neglect
diseas
clear
trend
toward
use
phenotyp
screen
place
targetbas
screen
particularli
persuas
ntd
well
bacteri
viral
fungal
pathogen
diseas
certainli
consid
difficult
convert
strong
target
hit
cell
permeabl
nontox
drug
identifi
target
nontox
compound
phenotyp
wholecel
activ
certainli
true
case
intracellular
parasit
compound
travers
one
host
membran
reach
final
target
studi
indic
mani
differ
research
group
global
perform
consider
amount
work
identifi
compound
repurpos
neglect
diseas
effort
still
cover
diseas
defin
tabl
due
space
restrict
cover
diseas
elig
prioriti
review
voucher
tabl
ii
repurpos
effort
eg
tuberculosi
malaria
etc
compound
identifi
variou
studi
describ
supplement
data
appear
gener
druglik
properti
one
would
expect
tabl
iii
case
diseas
transmiss
rampant
risk
begin
outweigh
cost
certain
govern
agenc
academ
institut
like
grant
fund
pursu
treatment
diseas
happen
ebola
zika
virus
instanc
academ
abl
partner
compani
increasingli
access
larg
librari
compound
screen
produc
hundr
ten
compound
high
likelihood
repurpos
group
tool
access
perform
vivo
work
suggest
clinic
studi
well
group
perform
vitro
screen
suggest
followup
vivo
studi
variou
research
use
comput
tool
molecular
dynam
dock
machin
learn
model
provid
consider
insight
specif
mechan
perform
high
throughput
screen
quickli
even
leverag
machin
learn
predict
novel
structur
howev
common
scientist
conclud
suggest
valid
vitro
vivo
ideal
perform
time
experi
collabor
chaga
diseas
abl
go
silico
vitro
vivo
singl
studi
ebola
went
silico
vitro
one
studi
vivo
efficaci
studi
anoth
group
gener
illustr
go
vitro
vivo
repurpos
drug
neglect
diseas
like
requir
success
integr
multipl
field
also
help
awar
promis
compound
convers
potenti
difficult
compound
occasion
see
compound
dispar
activ
exampl
clofazimin
antitrypanosom
agent
activ
cryptosporidium
parvum
pyronaridin
activ
chaga
diseas
ebola
fig
fexinidazol
recent
complet
clinic
trial
hat
also
consid
treatment
chaga
molecul
multipl
potenti
activ
neglect
tropic
diseas
may
common
think
could
point
common
target
across
diseas
screen
like
describ
herein
help
identifi
compound
bring
treatment
pipelin
diseas
hope
review
inspir
other
search
new
molecul
ntd
